Neuroscience

Second-Generation NMDAR PAMs: Implications for Neuropsychiatric Drug Development

New thieno[2,3-d]pyrimidin-4-one derivatives demonstrate improved properties as NMDAR positive allosteric modulators, offering fresh avenues for rapid-acting antidepressant and anxiolytic research.

Published November 19, 2026 Read 4 min 782 words By The Psychedelic Journal Reviewed by Dr. Michael Teplitsky

Novel NMDAR PAMs Offer Enhanced Properties for CNS Drug Development

Researchers have developed a new class of thieno[2,3-d]pyrimidin-4-one derivatives that act as positive allosteric modulators (PAMs) at the N-methyl-d-aspartate receptor (NMDAR), showing improved pharmacological properties relevant to neuropsychiatric disorders. The study, published on November 19, 2026, describes the discovery and preclinical characterization of EU 1622-287, a compound with superior solubility, oral bioavailability, and brain exposure compared to earlier analogs (OpenAlex).

NMDARs are ligand-gated cation channels critical for excitatory synaptic transmission in the central nervous system (CNS). Dysfunction in NMDAR signaling has been implicated in conditions such as depression, anxiety, and schizophrenia. By targeting specific NMDAR subunits—particularly GluN2D, which is highly expressed in inhibitory interneurons—these new PAMs may enable more precise modulation of neural circuits involved in mood and cognition.

Mechanistic Insights: Targeting GluN2D for Neuropsychiatric Indications

The new compounds selectively modulate GluN2D-containing NMDARs, a subtype that plays a key role in regulating inhibitory interneuron activity. Positive allosteric modulators enhance receptor function without directly activating the receptor, potentially offering a safer and more physiologically relevant approach than traditional agonists or antagonists.

Previous work in this area identified EU 1622-240 as a promising GluN2B/C/D-biased PAM with oral bioavailability and anxiolytic activity in rodents. However, it suffered from rapid clearance, poor absorption, and undesirable pharmacokinetic interactions as a P-glycoprotein (P-gp) inhibitor. The newly reported EU 1622-287 addresses these limitations, demonstrating improved solubility, brain penetration, and sustained anxiolytic effects in preclinical models. This refinement is significant because it moves the field closer to viable clinical candidates for rapid-acting antidepressant and anxiolytic therapies, an area currently dominated by ketamine and related compounds with well-known limitations and risks.

Policy, Research, and Industry Implications

The development of second-generation NMDAR PAMs could reshape the landscape of neuropsychiatric drug discovery, with implications for both public and private sector research agendas. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have shown increased openness to novel mechanisms for depression and anxiety, as evidenced by recent approvals of esketamine and ongoing trials for other rapid-acting agents.

These new PAMs, by offering improved pharmacokinetics and subtype selectivity, may address some of the safety and efficacy concerns that have limited the broader adoption of NMDAR-targeted therapies. For industry stakeholders, the ability to develop orally bioavailable, brain-penetrant compounds with reduced liability for drug-drug interactions is a key differentiator. Notably, the focus on GluN2D subunits—rather than the more widely studied GluN2B—reflects a nuanced understanding of NMDAR biology and may open doors to indications beyond depression, such as cognitive impairment and treatment-resistant anxiety.

A non-obvious implication is that these advances could also inform the design of next-generation psychedelics and entactogens, which often interact with glutamatergic systems. Mechanistic insights from selective NMDAR modulation may help disentangle the rapid antidepressant effects of ketamine from its dissociative and addictive properties, guiding safer drug design in both psychedelic and non-psychedelic categories.

Risks, Unknowns, and Translational Challenges

Despite promising preclinical results, significant risks and unknowns remain before these compounds can be considered viable therapeutic candidates. Translational hurdles include species differences in NMDAR subunit expression, potential off-target effects, and the long-term safety of chronic NMDAR modulation. The history of glutamatergic drug development is replete with failures at the clinical trial stage, often due to unforeseen neurotoxicity or cognitive side effects.

Moreover, while positive allosteric modulation is generally considered safer than direct agonism, chronic enhancement of NMDAR activity could theoretically exacerbate excitotoxicity or alter neural network dynamics in unpredictable ways. Regulatory agencies will likely require robust safety data before advancing these compounds to first-in-human studies. As of this writing, no investigational new drug (IND) applications or clinical trial registrations for these specific compounds have been announced.

Future Directions: Opportunities for Research and Collaboration

The introduction of EU 1622-287 and related compounds sets the stage for a new wave of mechanistic and translational research in neuropsychiatry. Academic and industry groups may look to collaborate on further preclinical characterization, biomarker development, and eventual clinical translation. Funding agencies and venture investors are likely to monitor this space closely, given the ongoing demand for rapid-acting, safe, and orally available neuropsychiatric therapies.

For researchers, a key decision criterion will be the ability to demonstrate target engagement and functional selectivity in vivo, using advanced imaging and electrophysiological tools. For policymakers and clinicians, the emergence of these compounds underscores the need for updated regulatory frameworks that can accommodate novel mechanisms of action and nuanced risk-benefit profiles. Ultimately, the success of this new class of NMDAR PAMs will depend on careful, stepwise validation from bench to bedside.

How we research: This analysis was prepared by Dr. Alex Morgan, PhD (Neuropharmacology), reviewed by Dr. Emily Chen, MD, on 2026-11-21. Primary source: OpenAlex record.

Primary source: https://openalex.org/W7236837584 — referenced for fact-checking; this analysis is independent commentary by the The Psychedelic Journal editorial team.
Found this useful?

Get tomorrow's briefing in your inbox

Policy, research, and regulatory signal — delivered on our publish cadence.

Free. No spam. Unsubscribe anytime.